Frédérique Kuhnowski

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial

Catherine Cordonnier, Cécile Pautas, Sébastien Maury et al. · Clinical Infectious Diseases · 2009 · 387 citations

Pharmacy, Infectious Diseases, Oncology +17

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2021 · 175 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot et al. · The Lancet Oncology · 2024 · 112 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Multiple Myeloma Treatment Response Assessment with Whole-Body Dynamic Contrast-enhanced MR Imaging

Chieh Lin, Alain Luciani, Karim Belhadj et al. · Radiology · 2010 · 88 citations

Medicine, Hematology, Radiology +16